Literature DB >> 22322584

Antithrombotic therapy in heart failure.

F W A Verheugt1.   

Abstract

Patients with congestive heart failure have a significant risk of stroke due to thromboembolism from the dilated left ventricle. Two relatively small trials suggest that oral anticoagulation with vitamin-K antagonists may reduce this risk when compared with placebo, aspirin or clopidogrel. However, more studies are eagerly awaited. So far, physicians seeing patients with heart failure should decide who needs antithrombotic prophylaxis on a case-by-case basis, especially since most heart failure patients have significant comorbidity precluding the use of oral anticoagulant.

Entities:  

Year:  2012        PMID: 22322584      PMCID: PMC3303021          DOI: 10.1007/s12471-012-0250-5

Source DB:  PubMed          Journal:  Neth Heart J        ISSN: 1568-5888            Impact factor:   2.380


  6 in total

Review 1.  Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review.

Authors:  Koon K Teo; Salim Yusuf; Marc Pfeffer; Christian Torp-Pedersen; Lars Kober; Alistair Hall; Janice Pogue; Roberto Latini; Rory Collins
Journal:  Lancet       Date:  2002-10-05       Impact factor: 79.321

2.  Aspirin use in older patients with heart failure and coronary artery disease: national prescription patterns and relationship with outcomes.

Authors:  Frederick A Masoudi; Pam Wolfe; Edward P Havranek; Saif S Rathore; JoAnne M Foody; Harlan M Krumholz
Journal:  J Am Coll Cardiol       Date:  2005-09-20       Impact factor: 24.094

3.  Ventricular dysfunction and the risk of stroke after myocardial infarction.

Authors:  E Loh; M S Sutton; C C Wun; J L Rouleau; G C Flaker; S S Gottlieb; G A Lamas; L A Moyé; S Z Goldhaber; M A Pfeffer
Journal:  N Engl J Med       Date:  1997-01-23       Impact factor: 91.245

4.  Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial.

Authors:  Barry M Massie; Joseph F Collins; Susan E Ammon; Paul W Armstrong; John G F Cleland; Michael Ezekowitz; Syed M Jafri; William F Krol; Christopher M O'Connor; Kevin A Schulman; Koon Teo; Stuart R Warren
Journal:  Circulation       Date:  2009-03-16       Impact factor: 29.690

5.  The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics.

Authors:  Barry M Massie; William F Krol; Susan E Ammon; Paul W Armstrong; John G Cleland; Joseph F Collins; Michael Ezekowitz; Syed M Jafri; Christopher M O'Connor; Milton Packer; Kevin A Schulman; Koon Teo; Stuart Warren
Journal:  J Card Fail       Date:  2004-04       Impact factor: 5.712

6.  The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure.

Authors:  J G F Cleland; I Findlay; S Jafri; G Sutton; R Falk; C Bulpitt; C Prentice; I Ford; Adele Trainer; P A Poole-Wilson
Journal:  Am Heart J       Date:  2004-07       Impact factor: 4.749

  6 in total
  3 in total

1.  Neurocardiology: close interaction between heart and brain.

Authors:  E E van der Wall; W H van Gilst
Journal:  Neth Heart J       Date:  2013-02       Impact factor: 2.380

2.  The new oral anticoagulants in atrial fibrillation: an update.

Authors:  F W A Verheugt
Journal:  Neth Heart J       Date:  2013-11       Impact factor: 2.380

3.  Coronary and cerebral air embolism: a rare complication of computed tomography-guided transthoracic lung biopsy.

Authors:  D R Smit; S A Kleijn; W G de Voogt
Journal:  Neth Heart J       Date:  2013-10       Impact factor: 2.380

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.